These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 25609941

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    Caillaud D, Le Merre C, Martinat Y, Aguilaniu B, Pavia D.
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial.
    Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A.
    Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development.
    Anzueto A, Miravitlles M.
    Respir Res; 2020 Jul 29; 21(1):199. PubMed ID: 32727455
    [Abstract] [Full Text] [Related]

  • 32. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.
    Rau-Berger H, Mitfessel H, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2010 Oct 10; 5():367-73. PubMed ID: 21103403
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Bronchodilator Effect of Tiotropium via Respimat®Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD).
    Ogasawara T, Sakata J, Aoshima Y, Tanaka K, Yano T, Kasamatsu N.
    Intern Med; 2017 Sep 15; 56(18):2401-2406. PubMed ID: 28824055
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies.
    Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, Blatchford J, Pavia D, Hodder R.
    Int J Chron Obstruct Pulmon Dis; 2010 Aug 09; 5():197-208. PubMed ID: 20714373
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
    Tang Y, Massey D, Zhong NS.
    Chin Med J (Engl); 2013 Aug 09; 126(19):3603-7. PubMed ID: 24112149
    [Abstract] [Full Text] [Related]

  • 37. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
    Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, Bateman E.
    Respir Med; 2008 Jan 09; 102(1):32-41. PubMed ID: 17996436
    [Abstract] [Full Text] [Related]

  • 38. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants.
    Calverley PMA, Mueller A, Fowler A, Metzdorf N, Wise RA.
    Ann Am Thorac Soc; 2018 Feb 09; 15(2):200-208. PubMed ID: 28957643
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C, Chong J, Poole P.
    Cochrane Database Syst Rev; 2012 Jul 11; (7):CD009285. PubMed ID: 22786525
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.